Core Insights - The company announced a global exclusive licensing agreement with Dianthus Therapeutics, Inc. to jointly advance the novel anti-BDCA2-TACI bispecific fusion protein LBL-047 [1] - LBL-047 has received IND approval for clinical trials in the United States and is under IND review in mainland China [1] Financial Terms - Dianthus will obtain exclusive rights for the research, development, and commercialization of LBL-047 outside Greater China [1] - The company will receive an upfront payment of up to $38 million, potential near-term milestone payments, and up to $1 billion in potential milestone payments related to clinical development, regulatory, and commercialization [1] - The company will also receive tiered royalties on net sales outside Greater China [1] Product Potential - LBL-047 targets BAFF/APRIL and BDCA2, showing therapeutic potential for various autoimmune diseases [1] - The drug is designed to reduce dosing frequency and improve patient compliance through glycosylation modifications and Fc region engineering [1]
维立志博-B与Dianthus签订LBL-047全球独家许可协议